Factors determining variation in colour morph frequencies in invasive Harmonia axyridis populations

The Harlequin ladybird Harmonia axyridis Pallas, native to eastern Asia, is an invasive, non-native species that has recently achieved an almost worldwide distribution. A conspicuous feature of this species is colour polymorphism of the elytra. In its native area, the populations consist of a recessive non-melanic morph, several dominant melanic morphs and small numbers of other (rare) morphs. The morph proportions in native populations have been intensively studied and vary with geographic area, climate and time. In contrast, colour polymorphism in invaded regions has been little studied. We examine and try to account for the morph frequencies observed across the different invaded regions. In America, monomorphic populations consist of the non-melanic morphs while European populations contain also melanic morphs. In particular geographic areas of Europe, the average percentage of the non-melanic morphs varied between 78 and 99%. It was highest in the lowlands of northern Italy and central and northern Europe and decreased in the Alps and western (Spain, UK) and eastern (southeast Russia) margins of the recently invaded area. In central Europe the frequency of the non-melanic morphs decreased over the course of the year but increased over the years from 2010 to 2018. The local differences might thus arise through gradual change of the morph composition of the founder invasive, non-native population. However, the variation in non-melanic morph frequency was not correlated with climatic characteristics that might affect coccinellid polymorphism. The observed rate of change in morph proportions in our data was too small to explain the diversification of what was supposedly a uniform invasive, non-native population at the point of introduction

Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

In patients receiving anticoagulant therapy for venous thromboembolism (VTE), the important issue of anemia influence on the risk of bleeding has not been consistently studied. We used the large registry data RIETE (Registro Informatizado Enfermedad Tromboembólica) to compare the rate of major bleeding in patients receiving anticoagulant therapy for VTE according to the presence or absence of anemia at baseline. Patients with or without cancer were separately studied. Until August 2016, 63492 patients had been enrolled. Of these, 21652 (34%) had anemia and 14312 (23%) had cancer. Anemia was found in 57% of the patients with cancer and in 28% without (odds ratio 3.46; 95% CI 3.33-3.60). During the course of anticoagulant therapy, 680 patients with cancer had a major bleeding event (gastrointestinal tract 43%, intracranial 14%, hematoma 12%). Cancer patients with anemia had a higher rate of major bleeding (rate ratio [RR]: 2.52; 95% CI 2.14-2.97) and fatal bleeding (RR 2.73; 95% CI 1.95-3.86) than those without anemia. During the course of anticoagulation, 1133 patients without cancer had major bleeding (gastrointestinal tract 32%, hematoma 24%, intracranial 21%). Patients with anemia had a higher rate of major bleeding (RR 2.84; 95% CI 2.52-2.39) and fatal bleeding (RR 2.76; 95% CI 2.07-3.67) than those without. On a multivariable analysis, anemia independently predicted the risk for major bleeding in patients with and without cancer (hazard ratios: 1.66; 95% CI 1.40-1.96 and 1.95; 95% CI 1.72-2.20, respectively). During anticoagulation for VTE, both cancer- and non-cancer anemic patients had a higher risk for major bleeding than those without anemia. In anemic patients (with or without cancer), the rate of major bleeding during the course of anticoagulant therapy exceeded the rate of VTE recurrences. In patients without anemia the rate of major bleeding was lower than the rate of VTE recurrences